Recent Updates
Recently added Catalysts
BLTE Positive Sentiment

Belite Bio to Participate in the BTIG Ophthalmology Day

Monday, November 20, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Belite Bio, a clinical-stage biopharmaceutical company, announced its participation in the BTIG Ophthalmology Day on November 27, 2023. The event will include a fireside chat and one-on-one meetings with investors. This initiative underscores Belite's commitment to addressing degenerative retinal diseases and engaging with the investment community.
Price reaction · baseline $37.2 (2023-11-17 close) · clean, no other BLTE news in the window
day 0 close · peak
+2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Belite Bio is actively engaging with investors and stakeholders.
  • Participation in the BTIG Ophthalmology Day highlights the company's focus on eye health.
  • Management's visibility could enhance investor confidence.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+33%
120-day peak, hindsight
Typical move
6.1%
average across 7 past catalysts
Lead asset
Tinlarebant
Phase 3 · Geographic Atrophy

Full Press Release Details

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that management will participate in a fireside chat at the BTIG Ophthalmology Day on Monday, November 27, 2023, at 3:00 p.m. ET.
The Belite management team will be participating in one-on-one meetings at the event. Investors interested in meeting with Belite at the conference should contact their BTIG representative.
Media and Investor Relations Contacts:

Frequently Asked Questions

What company is participating in BTIG Ophthalmology Day?

Belite Bio, Inc. will participate in the BTIG Ophthalmology Day.

When is the Belite Bio fireside chat?

The fireside chat is scheduled for November 27, 2023, at 3:00 p.m. ET.

Who should contact for meetings with Belite at the event?

Investors interested in meetings should contact their BTIG representative.

What does Belite Bio focus on developing?

Belite Bio focuses on novel therapeutics for degenerative retinal diseases.

How can media contact Belite Bio?

Media can reach Belite at belite@argotpartners.com.

ShareAdd on Google
Tags: BLTE Viatris Investor Conferences Healthcare Belite Bio BTIG ophthalmology retinal diseases
Last updated: Nov 20, 2023

Biotech snapshot

Lead asset
TinlarebantPhase 3
Geographic Atrophy →

Catalyst track record

+33%
best trade around BLTE's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for BLTE.

See every catalyst's timing & PoA →